Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Magy Onkol ; 61(4): 375-382, 2017 Dec 18.
Artigo em Húngaro | MEDLINE | ID: mdl-29257158

RESUMO

The present review about the history of anticancer drug research in Hungary intends to call attention to the importance of studies on their mode of action. Several lines of evidence suggest that clinically usable oncopharmacological properties could be revealed by this way. Among the numerous compounds certain alkylating sugar alcohols and 2'-deoxyuridine derivatives were submitted to detailed investigations concerning their mode of action. Myelobromol with selective action on the myeloid elements of bone marrow has been justified for its application in chronic myeloid leukemia therapy and also in bone marrow ablation before transplantation. Mitolactol is able to cross bloodbrain barrier, consequently could control certain brain tumors. 5-etil-2'-deoxyuridine by reducing dihydropyrimidine dehydrogenase activity is able to increase 5-fluorouracil concentration in the blood, resulting in improved antitumor effect. In contrast, 5-hexil-2'-deoxyuridine, as an inhibitor of glycoconjugate pathway by reducing heparan sulfate production, has the ability to prevent metastasis. Noteworthy, the remarkable effects of vinca alkaloids, antiestrogens, and GNRH analogues were also presented in this review.


Assuntos
Antineoplásicos Alquilantes/farmacologia , Desenho de Fármacos , Mitobronitol/farmacologia , Pesquisa Farmacêutica/normas , Melhoria de Qualidade , Antineoplásicos Alquilantes/uso terapêutico , Bases de Dados Factuais , Previsões , Humanos , Hungria , Manomustina/farmacologia , Manomustina/uso terapêutico , Mitobronitol/uso terapêutico , Mitolactol/farmacologia , Mitolactol/uso terapêutico , Pesquisa Farmacêutica/tendências , Farmacologia Clínica/normas , Farmacologia Clínica/tendências , Estudos Retrospectivos
2.
Hum Immunol ; 61(2): 101-10, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10717801

RESUMO

Chimerism is an exceptional immunogenetic state, characterized by the survival and collaboration of cell populations originated from two different individuals. The prerequisits to induce chimerism are immuno-suppression, myeloablation, or severe immunodeficiency of the recipients on the one side and donor originated immuno-hematopoietic cells in the graft on the other. The pathologic or special immunogenetic conditions to establish chimerism are combined with bone marrow transplantation, transfusion, and various kinds of solid organ grafting. Different types of chimerism are known including complete, mixed and mosaic, or split chimerism. There are various methods used to detect the type of chimera state, depending on the immunogenetic differences between the donor and recipient. The induction of complete or mixed chimerism is first determinated by the effect of myeloablative therapy. The chimera state seems to be one of the leading factors to influence the course of the post-transplant period, the frequency and severity of GVHD, and the rate of relapse. However, the most important contribution of the chimeric state is in development of graft versus leukemia effect. A new conditioning protocol (DBM/Ara-C/Cy) for allogeneic BMT in CML patients and its consequence on chimera state and GVL effect is demonstrated.


Assuntos
Transplante de Medula Óssea/imunologia , Quimeras de Transplante/imunologia , Antineoplásicos Alquilantes/farmacologia , Ciclofosfamida/farmacologia , Citarabina/farmacologia , Doença Enxerto-Hospedeiro/imunologia , Humanos , Imunossupressores/farmacologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Mitobronitol/farmacologia , Quimeras de Transplante/efeitos dos fármacos , Resultado do Tratamento
3.
Anal Biochem ; 225(2): 328-32, 1995 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-7762799

RESUMO

The interaction between 23 anticancer drugs and gamma-cyclodextrin (gamma-CD) was studied by reversed-phase charge-transfer thin-layer chromatography and the relative strength of interaction was calculated. gamma-CD formed inclusion complexes with 14 compounds, the complex always being more or less hydrophobic than the uncomplexed drug. The inclusion-forming capacity of a drug differed considerably depending on its chemical structure. The linear correlation between the hydrophobicity and the specific hydrophobic surface area of anticancer drugs indicated that they can be considered a homologous series of compounds, although their chemical structures are highly different.


Assuntos
Antineoplásicos/química , Ciclodextrinas/química , gama-Ciclodextrinas , Antineoplásicos/farmacologia , Carboplatina/química , Carboplatina/farmacologia , Cromatografia/métodos , Ciclodextrinas/metabolismo , Mesilatos/química , Mesilatos/farmacologia , Mitobronitol/química , Mitobronitol/farmacologia , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...